20-F 1 wdh-20231231x20f.htm FORM 20-F
2023FY0001823986false801904979801904979http://fasb.org/us-gaap/2023#OperatingExpenseshttp://fasb.org/us-gaap/2023#OperatingExpenseshttp://fasb.org/us-gaap/2023#OperatingExpensestruehttp://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMemberP6Yhttp://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense120352600037016220100001823986wdh:YifangdaMember2021-05-310001823986country:CNwdh:SmallEnterprisesWithLowProfitsMember2023-01-012023-12-310001823986country:CNwdh:SmallEnterprisesWithLowProfitsMember2022-01-012022-12-310001823986us-gaap:EmployeeStockOptionMemberwdh:TwoThousandTwentyOneShareIncentivePlanMember2021-01-012021-12-310001823986wdh:PrivateCompanyMember2021-12-310001823986wdh:SupervalleyIncMember2023-10-310001823986wdh:ZunshengBeijingInvestmentManagementCo.LtdMember2021-05-310001823986wdh:CustomerDMemberwdh:AccountsReceivableAndContractAssetsMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001823986wdh:CustomerCMemberwdh:AccountsReceivableAndContractAssetsMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001823986wdh:CustomerBMemberwdh:AccountsReceivableAndContractAssetsMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001823986wdh:CustomerAMemberwdh:AccountsReceivableAndContractAssetsMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001823986wdh:AccountsReceivableAndContractAssetsMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001823986wdh:CustomerDMemberwdh:AccountsReceivableAndContractAssetsMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001823986wdh:CustomerCMemberwdh:AccountsReceivableAndContractAssetsMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001823986wdh:CustomerBMemberwdh:AccountsReceivableAndContractAssetsMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001823986wdh:CustomerAMemberwdh:AccountsReceivableAndContractAssetsMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001823986wdh:AccountsReceivableAndContractAssetsMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001823986wdh:ShenzhenCunzhenQiushiTechnologyCoLtdMember2023-06-300001823986wdh:HainanPuluoMedicalTechnologyCo.Ltd.Memberwdh:TrademarkAndSoftwareCopyright.Member2021-12-310001823986wdh:HainanPuluoMedicalTechnologyCo.Ltd.Memberwdh:MedicalInstitutionLicenseMember2021-12-310001823986wdh:HainanPuluoMedicalTechnologyCo.Ltd.Member2021-12-310001823986wdh:HainanPuluoMedicalTechnologyCo.Ltd.Member2020-08-310001823986country:HK2018-04-012018-04-010001823986us-gaap:EmployeeStockOptionMember2021-05-012021-05-310001823986wdh:CustomerDMemberwdh:AccountsReceivableAndContractAssetsMemberus-gaap:CustomerConcentrationRiskMember2023-12-310001823986wdh:CustomerCMemberwdh:AccountsReceivableAndContractAssetsMemberus-gaap:CustomerConcentrationRiskMember2023-12-310001823986wdh:CustomerBMemberwdh:AccountsReceivableAndContractAssetsMemberus-gaap:CustomerConcentrationRiskMember2023-12-310001823986wdh:CustomerAMemberwdh:AccountsReceivableAndContractAssetsMemberus-gaap:CustomerConcentrationRiskMember2023-12-310001823986wdh:AccountsReceivableAndContractAssetsMemberus-gaap:CustomerConcentrationRiskMember2023-12-310001823986wdh:CustomerDMemberwdh:AccountsReceivableAndContractAssetsMemberus-gaap:CustomerConcentrationRiskMember2022-12-310001823986wdh:CustomerCMemberwdh:AccountsReceivableAndContractAssetsMemberus-gaap:CustomerConcentrationRiskMember2022-12-310001823986wdh:CustomerBMemberwdh:AccountsReceivableAndContractAssetsMemberus-gaap:CustomerConcentrationRiskMember2022-12-310001823986wdh:CustomerAMemberwdh:AccountsReceivableAndContractAssetsMemberus-gaap:CustomerConcentrationRiskMember2022-12-310001823986wdh:AccountsReceivableAndContractAssetsMemberus-gaap:CustomerConcentrationRiskMember2022-12-310001823986us-gaap:VariableInterestEntityPrimaryBeneficiaryMemberwdh:ZongqingXiangqianMember2023-01-012023-12-310001823986us-gaap:VariableInterestEntityPrimaryBeneficiaryMemberwdh:ShuidiInsuranceBrokerageCo.LtdMember2023-01-012023-12-310001823986us-gaap:VariableInterestEntityPrimaryBeneficiaryMemberwdh:ShuidiHulianMember2023-01-012023-12-310001823986us-gaap:VariableInterestEntityPrimaryBeneficiaryMemberwdh:ShuidiHubaoMember2023-01-012023-12-310001823986us-gaap:VariableInterestEntityPrimaryBeneficiaryMemberwdh:BeijingYifanFengshunMedicalTechnologyMember2023-01-012023-12-310001823986srt:SubsidiariesMemberwdh:WaterdropTechnologyMember2023-01-012023-12-310001823986srt:SubsidiariesMemberwdh:WaterdropGroupHkLimitedMember2023-01-012023-12-3100018239862021-09-072021-09-070001823986wdh:ShareRepurchaseProgramMember2023-09-060001823986wdh:ShareRepurchaseProgramMember2022-09-080001823986wdh:ShareRepurchaseProgramMember2021-09-070001823986wdh:ShareRepurchaseProgramMemberwdh:AdsSharesMember2023-09-012023-09-300001823986wdh:ShareRepurchaseProgramMemberus-gaap:CommonClassAMember2023-09-012023-09-300001823986wdh:ShareRepurchaseProgramMemberwdh:AdsSharesMember2022-09-012022-09-300001823986wdh:ShareRepurchaseProgramMemberus-gaap:CommonClassAMember2022-09-012022-09-300001823986us-gaap:TreasuryStockCommonMember2022-01-012022-12-310001823986wdh:ShareRepurchaseProgramMemberwdh:AdsSharesMember2021-09-072021-09-070001823986wdh:ShareRepurchaseProgramMemberus-gaap:CommonClassAMember2021-09-072021-09-070001823986us-gaap:TreasuryStockCommonMember2021-01-012021-12-310001823986us-gaap:TreasuryStockCommonMember2023-01-012023-12-310001823986us-gaap:CommonStockMember2023-01-012023-12-310001823986us-gaap:CommonStockMember2022-01-012022-12-310001823986us-gaap:CommonClassAMemberus-gaap:IPOMember2021-05-072021-05-070001823986dei:AdrMemberus-gaap:IPOMember2021-05-072021-05-070001823986us-gaap:CommonStockMember2021-01-012021-12-310001823986srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2023-12-310001823986us-gaap:RetainedEarningsMember2023-12-310001823986us-gaap:AdditionalPaidInCapitalMember2023-12-310001823986us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001823986srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2022-12-310001823986us-gaap:RetainedEarningsMember2022-12-310001823986us-gaap:AdditionalPaidInCapitalMember2022-12-310001823986us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001823986us-gaap:RetainedEarningsMember2021-12-310001823986us-gaap:AdditionalPaidInCapitalMember2021-12-310001823986us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001823986us-gaap:RetainedEarningsMember2020-12-310001823986us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001823986us-gaap:TreasuryStockCommonMember2023-12-310001823986us-gaap:CommonStockMember2023-12-310001823986us-gaap:TreasuryStockCommonMember2022-12-310001823986us-gaap:CommonStockMember2022-12-310001823986us-gaap:TreasuryStockCommonMember2021-12-310001823986us-gaap:CommonStockMember2021-12-310001823986us-gaap:CommonStockMember2020-12-310001823986dei:AdrMemberus-gaap:IPOMember2021-05-070001823986us-gaap:RestrictedStockMemberwdh:SelectedManagementMember2020-10-310001823986wdh:FounderRestrictedStockMember2021-01-012021-12-310001823986wdh:FounderRestrictedStockMember2021-12-310001823986wdh:FounderRestrictedStockMember2020-12-310001823986us-gaap:RestrictedStockMember2018-01-012018-12-310001823986us-gaap:EmployeeStockOptionMemberwdh:TwoThousandEighteenShareIncentivePlanMember2023-01-012023-12-310001823986us-gaap:EmployeeStockOptionMemberwdh:TwoThousandEighteenShareIncentivePlanMember2022-01-012022-12-310001823986us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001823986wdh:ShenzhenCunzhenQiushiTechnologyCoLtdMemberus-gaap:EmployeeStockOptionMemberwdh:SlbShareIncentivePlanMember2023-12-310001823986wdh:ShenzhenCunzhenQiushiTechnologyCoLtdMemberus-gaap:EmployeeStockOptionMemberwdh:SlbShareIncentivePlanMember2023-09-300001823986wdh:ShenzhenCunzhenQiushiTechnologyCoLtdMemberus-gaap:EmployeeStockOptionMemberwdh:SlbShareIncentivePlanMember2022-12-310001823986us-gaap:EmployeeStockOptionMemberwdh:TwoThousandEighteenShareIncentivePlanMember2019-12-310001823986us-gaap:EmployeeStockOptionMemberwdh:TwoThousandEighteenShareIncentivePlanMember2019-01-012019-12-310001823986us-gaap:RestrictedStockMemberwdh:SelectedManagementMember2020-10-012020-10-310001823986srt:MinimumMember2023-01-012023-12-310001823986srt:MaximumMember2023-01-012023-12-310001823986srt:MinimumMember2022-01-012022-12-310001823986srt:MaximumMember2022-01-012022-12-310001823986wdh:ShenzhenCunzhenQiushiTechnologyCoLtdMembersrt:MinimumMemberus-gaap:EmployeeStockOptionMemberwdh:SlbShareIncentivePlanMember2023-01-012023-12-310001823986wdh:ShenzhenCunzhenQiushiTechnologyCoLtdMembersrt:MaximumMemberus-gaap:EmployeeStockOptionMemberwdh:SlbShareIncentivePlanMember2023-01-012023-12-310001823986wdh:ShenzhenCunzhenQiushiTechnologyCoLtdMemberus-gaap:EmployeeStockOptionMemberwdh:SlbShareIncentivePlanMember2023-01-012023-12-310001823986wdh:ShenzhenCunzhenQiushiTechnologyCoLtdMembersrt:MinimumMemberus-gaap:EmployeeStockOptionMemberwdh:SlbShareIncentivePlanMember2023-12-310001823986wdh:ShenzhenCunzhenQiushiTechnologyCoLtdMembersrt:MaximumMemberus-gaap:EmployeeStockOptionMemberwdh:SlbShareIncentivePlanMember2023-12-310001823986srt:MinimumMember2023-12-310001823986srt:MaximumMember2023-12-310001823986srt:MinimumMember2022-12-310001823986srt:MaximumMember2022-12-310001823986us-gaap:RestrictedStockMember2023-01-012023-12-310001823986us-gaap:RestrictedStockMember2022-01-012022-12-310001823986us-gaap:RestrictedStockUnitsRSUMemberwdh:TwoThousandEighteenShareIncentivePlanMember2023-12-310001823986us-gaap:RestrictedStockUnitsRSUMemberwdh:TwoThousandEighteenShareIncentivePlanMember2022-12-310001823986us-gaap:RestrictedStockUnitsRSUMemberwdh:TwoThousandEighteenShareIncentivePlanMember2021-12-310001823986us-gaap:RestrictedStockUnitsRSUMemberwdh:TwoThousandTwentyOneShareIncentivePlanMember2023-01-012023-12-310001823986us-gaap:RestrictedStockUnitsRSUMemberwdh:TwoThousandTwentyOneShareIncentivePlanMember2022-01-012022-12-310001823986us-gaap:RestrictedStockUnitsRSUMemberwdh:TwoThousandEighteenShareIncentivePlanMember2023-01-012023-12-310001823986us-gaap:RestrictedStockUnitsRSUMemberwdh:TwoThousandEighteenShareIncentivePlanMember2022-01-012022-12-310001823986us-gaap:RestrictedStockUnitsRSUMemberwdh:SelectedManagementMember2020-10-012020-10-310001823986us-gaap:EmployeeStockOptionMemberwdh:SelectedManagementMember2020-10-012020-10-310001823986srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMemberwdh:TwoThousandEighteenShareIncentivePlanMember2023-01-012023-12-310001823986srt:MinimumMemberus-gaap:EmployeeStockOptionMemberwdh:TwoThousandEighteenShareIncentivePlanMember2023-01-012023-12-310001823986srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMemberwdh:TwoThousandEighteenShareIncentivePlanMember2023-01-012023-12-310001823986srt:MaximumMemberus-gaap:EmployeeStockOptionMemberwdh:TwoThousandEighteenShareIncentivePlanMember2023-01-012023-12-310001823986wdh:ShenzhenCunzhenQiushiTechnologyCoLtdMemberus-gaap:EmployeeStockOptionMemberwdh:SlbShareIncentivePlanMember2022-01-012022-12-310001823986us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-12-310001823986us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-12-310001823986us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-12-310001823986us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-310001823986us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310001823986us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-310001823986us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-310001823986us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001823986us-gaap:RestrictedStockMember2021-01-012021-12-310001823986us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001823986us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-310001823986us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001823986us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001823986wdh:TencentGroupMemberus-gaap:AdvertisingMemberus-gaap:RelatedPartyMember2023-01-012023-12-310001823986wdh:TencentGroupMemberus-gaap:AdvertisingMemberus-gaap:RelatedPartyMember2022-01-012022-12-310001823986wdh:TencentGroupMemberus-gaap:AdvertisingMemberus-gaap:RelatedPartyMember2021-01-012021-12-310001823986wdh:CustomerDMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001823986wdh:CustomerCMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001823986wdh:CustomerBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001823986wdh:CustomerAMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001823986wdh:InsuranceBrokerageIncomeMemberus-gaap:ShortTermContractWithCustomerMember2023-01-012023-12-310001823986wdh:InsuranceBrokerageIncomeMemberus-gaap:LongTermContractWithCustomerMember2023-01-012023-12-310001823986us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001823986wdh:TechnicalServiceIncomeMember2023-01-012023-12-310001823986wdh:OtherRevenuesMember2023-01-012023-12-310001823986wdh:InsuranceBrokerageIncomeMember2023-01-012023-12-310001823986wdh:DigitalClinicalTrialSolutionIncomeMember2023-01-012023-12-310001823986wdh:CrowdfundingServiceFeesMember2023-01-012023-12-310001823986wdh:CustomerDMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001823986wdh:CustomerCMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001823986wdh:CustomerBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001823986wdh:CustomerAMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001823986wdh:InsuranceBrokerageIncomeMemberus-gaap:ShortTermContractWithCustomerMember2022-01-012022-12-310001823986wdh:InsuranceBrokerageIncomeMemberus-gaap:LongTermContractWithCustomerMember2022-01-012022-12-310001823986us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001823986wdh:TechnicalServiceIncomeMember2022-01-012022-12-310001823986wdh:OtherRevenuesMember2022-01-012022-12-310001823986wdh:InsuranceBrokerageIncomeMember2022-01-012022-12-310001823986wdh:DigitalClinicalTrialSolutionIncomeMember2022-01-012022-12-310001823986wdh:CrowdfundingServiceFeesMember2022-01-012022-12-310001823986wdh:CustomerDMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001823986wdh:CustomerCMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001823986wdh:CustomerBMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001823986wdh:CustomerAMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001823986wdh:InsuranceBrokerageIncomeMemberus-gaap:ShortTermContractWithCustomerMember2021-01-012021-12-310001823986wdh:InsuranceBrokerageIncomeMemberus-gaap:LongTermContractWithCustomerMember2021-01-012021-12-310001823986us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001823986wdh:TechnicalServiceIncomeMember2021-01-012021-12-310001823986wdh:OtherRevenuesMember2021-01-012021-12-310001823986wdh:ManagementFeeIncomeMember2021-01-012021-12-310001823986wdh:InsuranceBrokerageIncomeMember2021-01-012021-12-310001823986wdh:DigitalClinicalTrialSolutionIncomeMember2021-01-012021-12-310001823986wdh:TencentGroupMemberwdh:PaymentProcessingServicesMemberus-gaap:RelatedPartyMember2023-01-012023-12-310001823986wdh:TencentGroupMemberwdh:MarketingServicesMemberus-gaap:RelatedPartyMember2023-01-012023-12-310001823986wdh:TencentGroupMemberwdh:CloudTechnologyServicesFromTencentGroupMemberus-gaap:RelatedPartyMember2023-01-012023-12-310001823986wdh:OthersMemberwdh:OtherServicesMemberus-gaap:RelatedPartyMember2023-01-012023-12-310001823986us-gaap:RelatedPartyMember2023-01-012023-12-310001823986wdh:TencentGroupMemberwdh:PaymentProcessingServicesMemberus-gaap:RelatedPartyMember2022-01-012022-12-310001823986wdh:TencentGroupMemberwdh:MarketingServicesMemberus-gaap:RelatedPartyMember2022-01-012022-12-310001823986wdh:TencentGroupMemberwdh:CloudTechnologyServicesFromTencentGroupMemberus-gaap:RelatedPartyMember2022-01-012022-12-310001823986wdh:OthersMemberwdh:OtherServicesMemberus-gaap:RelatedPartyMember2022-01-012022-12-310001823986us-gaap:RelatedPartyMember2022-01-012022-12-310001823986wdh:TencentGroupMemberwdh:PaymentProcessingServicesMemberus-gaap:RelatedPartyMember2021-01-012021-12-310001823986wdh:TencentGroupMemberwdh:MarketingServicesMemberus-gaap:RelatedPartyMember2021-01-012021-12-310001823986wdh:TencentGroupMemberwdh:CloudTechnologyServicesFromTencentGroupMemberus-gaap:RelatedPartyMember2021-01-012021-12-310001823986wdh:OthersMemberwdh:OtherServicesMemberus-gaap:RelatedPartyMember2021-01-012021-12-310001823986us-gaap:RelatedPartyMember2021-01-012021-12-310001823986wdh:OfficeFurnitureAndEquipmentMember2023-12-310001823986wdh:ComputerAndElectronicEquipmentMember2023-12-310001823986us-gaap:SoftwareDevelopmentMember2023-12-310001823986us-gaap:OfficeEquipmentMember2023-12-310001823986us-gaap:LeaseholdImprovementsMember2023-12-310001823986wdh:ComputerAndElectronicEquipmentMember2022-12-310001823986us-gaap:SoftwareDevelopmentMember2022-12-310001823986us-gaap:OfficeEquipmentMember2022-12-310001823986us-gaap:LeaseholdImprovementsMember2022-12-310001823986us-gaap:IPOMember2021-05-072021-05-070001823986wdh:AdsSharesMemberus-gaap:IPOMember2021-05-012021-05-310001823986us-gaap:IPOMember2021-05-310001823986us-gaap:CommonClassAMemberus-gaap:IPOMember2021-03-310001823986wdh:HainanPuluoMedicalTechnologyCo.Ltd.Member2020-08-012020-08-310001823986wdh:ShenzhenCunzhenQiushiTechnologyCoLtdMember2023-07-012023-07-310001823986wdh:BeijingYifanFengshunMedicalTechnologyCoLtdMember2021-12-012021-12-310001823986wdh:TencentGroupMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:RelatedPartyMember2023-12-310001823986wdh:TencentGroupMemberus-gaap:RelatedPartyMember2023-12-310001823986wdh:TencentGroupMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:RelatedPartyMember2022-12-310001823986wdh:TencentGroupMemberus-gaap:RelatedPartyMember2022-12-310001823986wdh:TencentGroupMemberwdh:CloudTechnologyServicesFromTencentGroupMemberus-gaap:RelatedPartyMember2023-12-310001823986us-gaap:VariableInterestEntityPrimaryBeneficiaryMemberus-gaap:RelatedPartyMember2023-12-310001823986us-gaap:RelatedPartyMember2023-12-310001823986wdh:TencentGroupMemberwdh:OtherServicesMemberus-gaap:RelatedPartyMember2022-12-310001823986wdh:TencentGroupMemberwdh:CloudTechnologyServicesFromTencentGroupMemberus-gaap:RelatedPartyMember2022-12-310001823986us-gaap:VariableInterestEntityPrimaryBeneficiaryMemberus-gaap:RelatedPartyMember2022-12-310001823986us-gaap:RelatedPartyMember2022-12-310001823986us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001823986us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001823986us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001823986us-gaap:OperatingSegmentsMemberwdh:InsuranceMember2023-01-012023-12-310001823986us-gaap:OperatingSegmentsMemberwdh:CrowdfundingMember2023-01-012023-12-310001823986us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2023-01-012023-12-310001823986us-gaap:CorporateNonSegmentMember2023-01-012023-12-310001823986us-gaap:OperatingSegmentsMemberwdh:InsuranceMember2022-01-012022-12-310001823986us-gaap:OperatingSegmentsMemberwdh:CrowdfundingMember2022-01-012022-12-310001823986us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2022-01-012022-12-310001823986us-gaap:CorporateNonSegmentMember2022-01-012022-12-310001823986us-gaap:OperatingSegmentsMemberwdh:InsuranceMember2021-01-012021-12-310001823986us-gaap:OperatingSegmentsMemberwdh:CrowdfundingMember2021-01-012021-12-310001823986us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2021-01-012021-12-310001823986us-gaap:CorporateNonSegmentMember2021-01-012021-12-3100018239862021-12-012021-12-310001823986us-gaap:RetainedEarningsMember2023-01-012023-12-310001823986us-gaap:RetainedEarningsMember2022-01-012022-12-310001823986us-gaap:RetainedEarningsMember2021-01-012021-12-310001823986us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-01-012023-12-310001823986us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-01-012022-12-310001823986us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-01-012021-12-310001823986srt:SubsidiariesMemberwdh:WaterdropTechnologyMember2023-12-310001823986srt:SubsidiariesMemberwdh:WaterdropGroupHkLimitedMember2023-12-310001823986srt:ParentCompanyMembersrt:AffiliatedEntityMember2023-12-310001823986srt:ParentCompanyMembersrt:AffiliatedEntityMember2022-12-310001823986us-gaap:OperatingSegmentsMember2023-01-012023-12-310001823986us-gaap:OperatingSegmentsMember2022-01-012022-12-310001823986us-gaap:OperatingSegmentsMember2021-01-012021-12-310001823986wdh:InsuranceMember2023-01-012023-12-310001823986us-gaap:AllOtherSegmentsMember2021-01-012021-12-310001823986wdh:InsuranceMember2023-12-310001823986us-gaap:AllOtherSegmentsMember2023-12-310001823986wdh:InsuranceMember2022-12-310001823986us-gaap:AllOtherSegmentsMember2022-12-310001823986wdh:InsuranceMember2021-12-310001823986us-gaap:AllOtherSegmentsMember2021-12-310001823986wdh:InsuranceMember2020-12-310001823986us-gaap:AllOtherSegmentsMember2020-12-310001823986wdh:TrademarkAndSoftwareCopyright.Member2023-12-310001823986wdh:MedicalInstitutionLicenseMember2023-12-310001823986wdh:InsuranceAgencyLicenseMember2023-12-310001823986wdh:InsuranceAdjustingLicenseMember2023-12-310001823986wdh:BrokerageLicensesMember2023-12-310001823986wdh:TrademarkAndSoftwareCopyright.Member2022-12-310001823986wdh:MedicalInstitutionLicenseMember2022-12-310001823986wdh:InsuranceAgencyLicenseMember2022-12-310001823986wdh:InsuranceAdjustingLicenseMember2022-12-310001823986wdh:BrokerageLicensesMember2022-12-310001823986us-gaap:EmployeeStockOptionMember2023-12-310001823986us-gaap:VariableInterestEntityPrimaryBeneficiaryMembercountry:CN2023-01-012023-12-310001823986country:CNwdh:HighAndNewTechnologyEnterprisesMember2023-01-012023-12-310001823986wdh:InvestorHoldsLessThanTwentyFivePercentOfFieMember2023-01-012023-12-310001823986wdh:InvestorHoldsAtLeastTwentyFivePercentOfFieMember2023-01-012023-12-310001823986country:HK2023-01-012023-12-310001823986country:CN2023-01-012023-12-310001823986country:CNwdh:HighAndNewTechnologyEnterprisesMember2022-01-012022-12-310001823986dei:AdrMemberus-gaap:SubsequentEventMember2024-03-260001823986us-gaap:SubsequentEventMember2024-03-260001823986wdh:SupervalleyIncMember2023-10-012023-10-310001823986wdh:ZunshengBeijingInvestmentManagementCo.LtdMember2021-05-012021-05-310001823986wdh:CommonClassAAndBMemberus-gaap:IPOMember2023-12-310001823986us-gaap:CommonClassBMemberus-gaap:IPOMember2023-12-310001823986us-gaap:CommonClassAMemberus-gaap:IPOMember2023-12-310001823986us-gaap:EmployeeStockOptionMemberwdh:TwoThousandTwentyOneShareIncentivePlanMember2021-12-310001823986wdh:AdsSharesMemberus-gaap:IPOMember2021-05-310001823986us-gaap:CommonClassAMember2021-05-310001823986srt:ParentCompanyMemberus-gaap:CommonClassBMember2023-12-310001823986srt:ParentCompanyMemberus-gaap:CommonClassAMember2023-12-310001823986srt:ParentCompanyMemberus-gaap:CommonClassBMember2022-12-310001823986srt:ParentCompanyMemberus-gaap:CommonClassAMember2022-12-310001823986us-gaap:CommonClassBMember2022-12-310001823986us-gaap:CommonClassAMember2022-12-310001823986srt:ParentCompanyMember2023-01-012023-12-310001823986srt:ParentCompanyMember2022-01-012022-12-310001823986srt:ParentCompanyMember2021-01-012021-12-310001823986srt:ParentCompanyMember2021-12-310001823986srt:ParentCompanyMember2020-12-3100018239862020-12-3100018239862021-12-310001823986wdh:ShenzhenCunzhenQiushiTechnologyCoLtdMemberwdh:InsuranceBrokerageLicenseMember2023-12-310001823986wdh:ShenzhenCunzhenQiushiTechnologyCoLtdMemberus-gaap:TrademarksMember2023-12-310001823986wdh:ShenzhenCunzhenQiushiTechnologyCoLtdMember2023-12-310001823986wdh:ShenzhenCunzhenQiushiTechnologyCoLtdMember2023-07-310001823986wdh:BeijingYifanFengshunMedicalTechnologyCoLtdMember2021-12-310001823986us-gaap:FairValueInputsLevel2Member2023-12-310001823986us-gaap:FairValueInputsLevel2Member2022-12-310001823986wdh:HainanPuluoMedicalTechnologyCo.Ltd.Member2021-01-012021-12-310001823986wdh:SeriesPreAPreferredStockMember2023-01-012023-12-310001823986wdh:SeriesCPlusPreferredStockMember2023-01-012023-12-310001823986wdh:SeriesCPlusPlusPreferredStockMember2023-01-012023-12-310001823986wdh:SeriesAPlusPreferredStockMember2023-01-012023-12-310001823986us-gaap:SeriesDPreferredStockMember2023-01-012023-12-310001823986us-gaap:SeriesCPreferredStockMember2023-01-012023-12-310001823986us-gaap:SeriesBPreferredStockMember2023-01-012023-12-310001823986us-gaap:SeriesAPreferredStockMember2023-01-012023-12-310001823986us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001823986us-gaap:RestrictedStockMember2023-01-012023-12-310001823986us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001823986wdh:SeriesPreAPreferredStockMember2022-01-012022-12-310001823986wdh:SeriesCPlusPreferredStockMember2022-01-012022-12-310001823986wdh:SeriesCPlusPlusPreferredStockMember2022-01-012022-12-310001823986wdh:SeriesAPlusPreferredStockMember2022-01-012022-12-310001823986us-gaap:SeriesDPreferredStockMember2022-01-012022-12-310001823986us-gaap:SeriesCPreferredStockMember2022-01-012022-12-310001823986us-gaap:SeriesBPreferredStockMember2022-01-012022-12-310001823986us-gaap:SeriesAPreferredStockMember2022-01-012022-12-310001823986us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001823986us-gaap:RestrictedStockMember2022-01-012022-12-310001823986us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001823986wdh:SeriesPreAPreferredStockMember2021-01-012021-12-310001823986wdh:SeriesCPlusPreferredStockMember2021-01-012021-12-310001823986wdh:SeriesCPlusPlusPreferredStockMember2021-01-012021-12-310001823986wdh:SeriesAPlusPreferredStockMember2021-01-012021-12-310001823986us-gaap:SeriesDPreferredStockMember2021-01-012021-12-310001823986us-gaap:SeriesCPreferredStockMember2021-01-012021-12-310001823986us-gaap:SeriesBPreferredStockMember2021-01-012021-12-310001823986us-gaap:SeriesAPreferredStockMember2021-01-012021-12-310001823986us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001823986us-gaap:RestrictedStockMember2021-01-012021-12-310001823986us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001823986srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2023-12-310001823986srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2022-12-310001823986wdh:ShenzhenCunzhenQiushiTechnologyCoLtdMemberus-gaap:EmployeeStockOptionMemberwdh:SlbShareIncentivePlanMember2023-09-012023-09-300001823986us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310001823986us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-3100018239862022-01-012022-12-310001823986us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-3100018239862021-01-012021-12-310001823986us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-12-310001823986srt:ParentCompanyMember2023-12-3100018239862023-12-310001823986us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-12-310001823986srt:ParentCompanyMember2022-12-3100018239862022-12-310001823986dei:AdrMember2023-01-012023-12-310001823986us-gaap:CommonClassAMember2023-01-012023-12-310001823986us-gaap:CommonClassBMember2023-12-310001823986us-gaap:CommonClassAMember2023-12-310001823986dei:AdrMember2023-12-310001823986dei:BusinessContactMember2023-01-012023-12-3100018239862023-01-012023-12-31iso4217:HKDwdh:Votexbrli:sharesiso4217:CNYiso4217:USDxbrli:pureiso4217:USDxbrli:sharesiso4217:CNYxbrli:sharesiso4217:USDiso4217:CNYwdh:itemwdh:segment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 20-F

(Mark One)

REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2023.

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of event requiring this shell company report ________

For the transition period from ________ to ________

Commission file number:001-40376

Waterdrop Inc.

(Exact name of Registrant as specified in its charter)

N/A

(Translation of Registrant’s name into English)

Cayman Islands

(Jurisdiction of incorporation or organization)

Block C, Wangjing Science and Technology Park

No. 2 Lize Zhonger Road

Chaoyang District, Beijing 100102

People’s Republic of China

+86 10 5339-4997

(Address of Principal Executive Offices)

Guang Yang, Vice President of Finance and General Manager of International Business

Telephone: +86 10 5339-4997

Email:IR@shuidi-inc.com

Block C, Wangjing Science and Technology Park

No. 2 Lize Zhonger Road

Chaoyang District, Beijing 100102

People’s Republic of China

(Name, Telephone, Email and/or Facsimile Number and Address of Company Contact Person)

Securities registered or to be registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

American depositary shares (each ADS represents ten of our Class A ordinary shares, par value US$0.000005 per share)

 

WDH

 

New York Stock Exchange

Class A ordinary shares, par value US$0.000005 per share*

 

 

 

New York Stock Exchange

*

Not for trading, but only in connection with the listing on the New York Stock Exchange of American depositary shares.

Securities registered or to be registered pursuant to Section 12(g) of the Act:

None

(Title of Class)

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:

None

(Title of Class)

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report.

2,899,717,031 Class A ordinary shares (excluding 382,539,490 Class A ordinary shares, comprising of Class A ordinary shares issued to the depositary for bulk issuance of ADSs and reserved for future issuances upon the exercise or vesting of awards granted under share incentive plans, and Class A ordinary shares in the form of ADSs held in treasury) and 801,904,979 Class B ordinary shares, par value US$0.000005 per share, as of December 31, 2023.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.     Yes      No

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.     Yes      No

Note — Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes      No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes      No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

 

  

Accelerated filer

 

 

Non-accelerated filer

 

 

 

 

  

 

 

 

 

Emerging growth company

 

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     Yes      No

† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.     Yes      No

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to§240.10D-1(b).

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S. GAAP  

 

        International Financial Reporting Standards as issued

 

  

 

  

Other  

 

 

        by the International Accounting Standards Board

 

  

 

  

 

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.     Item    17      Item 18

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes      No

(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS)

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.     Yes      No

TABLE OF CONTENTS

Page

INTRODUCTION

1

FORWARD-LOOKING INFORMATION

2

PART I

3

Item 1.

Identity of Directors, Senior Management and Advisers

3

Item 2.

Offer Statistics and Expected Timetable

3

Item 3.

Key Information

3

Item 4.

Information on the Company

68

Item 4A.

Unresolved Staff Comments

110

Item 5.

Operating and Financial Review and Prospects

110

Item 6.

Directors, Senior Management and Employees

125

Item 7.

Major Shareholders and Related Party Transactions

137

Item 8.

Financial Information

138

Item 9.

The Offer and Listing

139

Item 10.

Additional Information

140

Item 11.

Quantitative and Qualitative Disclosures about Market Risk

155

Item 12.

Description of Securities Other than Equity Securities

155

PART II

158

Item 13.

Defaults, Dividend Arrearages and Delinquencies

158

Item 14.

Material Modifications to the Rights of Security Holders and Use of Proceeds

158

Item 15.

Controls and Procedures

158

Item 16A.

Audit Committee Financial Expert

159

Item 16B.

Code of Ethics

159

Item 16C.

Principal Accountant Fees and Services

159

Item 16D.

Exemptions from the Listing Standards for Audit Committees

160

Item 16E.

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

160

Item 16F.

Change in Registrant’s Certifying Accountant

160

Item 16G.

Corporate Governance

161

Item 16H.

Mine Safety Disclosure

161

Item 16I.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

161

Item 16J.

Insider Trading Policies

161

Item 16K.

Cybersecurity

162

PART III

163

Item 17.

Financial Statements

163

Item 18.

Financial Statements

163

Item 19.

Exhibits

163

SIGNATURES

168

i

INTRODUCTION

Unless otherwise indicated or the context otherwise requires, references in this annual report to:

“ADRs” are to the American depositary receipts which may evidence the ADSs;
“ADSs” are to the American depositary shares, each of which represents ten Class A ordinary shares;
“China” or the “PRC” are to the People’s Republic of China, including Hong Kong, Macau and Taiwan; and “mainland China” refers to the People’s Republic of China, excluding Hong Kong, Macau and Taiwan. The operational risks associated with being based in and having operations in mainland China also apply to operations in Hong Kong. While entities and businesses in Hong Kong operate under different sets of laws from mainland China, the legal risks associated with being based in and having operations in mainland China could apply to our operations in Hong Kong, if the laws applicable to mainland China become applicable to entities and businesses in Hong Kong in the future;
“Class A ordinary shares” refer to our Class A ordinary shares, par value US$0.000005 per share; “Class B ordinary shares” refer to our Class B ordinary shares, par value US$0.000005 per share;
“CRO” are to Contract Research Organization;
“CSO” are to Contract Sales Organization;
“FYP” are to first year premiums, which include all premiums that policyholders are obligated to pay for short-term policies and the premiums that policyholders are obligated to pay in the first policy year for long-term policies;
“Hong Kong” or “HK” are to the Hong Kong Special Administrative Region of the PRC;
“ordinary shares” are to our Class A ordinary shares and Class B ordinary shares, par value US$0.000005 per share;
“the VIEs” are to Beijing Zhuiqiu Jizhi Technology Co., Ltd., or Zhuiqiu Jizhi, Beijing Shuidi Hubao Technology Co., Ltd., or Shuidi Hubao, Beijing Shuidi Hulian Technology Co., Ltd., or Shuidi Hulian, Beijing Zongqing Xiangqian Technology Co., Ltd., or Zongqing Xiangqian, and Beijing Guangmu Weichen Technology Co., Ltd., or Guangmu Weichen;
“our WFOE” are to Waterdrop Technology Group Co., Ltd., or Waterdrop Technology, formerly known as Beijing Absolute Health Co., Ltd.;
“RMB” and “Renminbi” are to the legal currency of China;
“Shenlanbao” are to Shenzhen Cunzhen Qiushi Technology Co., Ltd. and its subsidiaries;
“US$,” “U.S. dollars,” “$,” and “dollars” are to the legal currency of the United States; and
“Waterdrop,” “we,” “us,” “our company” and “our” are to Waterdrop Inc., our Cayman Islands holding company and its subsidiaries. We conduct our operations primarily through (i) our subsidiaries in mainland China and (ii) the VIEs, with which we maintain contractual agreements. The consolidated VIEs are the companies that are incorporated and conducting operations in mainland China, and their financial results have been consolidated into our consolidated financial statements under U.S. GAAP for accounting purposes.

Our reporting currency is the Renminbi. This annual report also contains translations of certain foreign currency amounts into U.S. dollars for the convenience of the reader. Unless otherwise stated, all translations of Renminbi into U.S. dollars were made at RMB7.0999 to US$1.00, the exchange rate set forth in the H.10 statistical release of the Federal Reserve Board on December 29, 2023. We make no representation that the Renminbi or U.S. dollars amounts referred to in this annual report could have been or could be converted into U.S. dollars or Renminbi, as the case may be, at any particular rate or at all.

Due to rounding, numbers presented throughout this annual report may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

1

FORWARD-LOOKING INFORMATION

This annual report contains forward-looking statements that involve risks and uncertainties. All statements other than statements of current or historical facts are forward-looking statements. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements.

You can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “likely to” or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements include, but are not limited to, statements about:

our mission, goals and strategies;
our future business development, financial conditions and results of operations;
the growth of the insurance, medical crowdfunding and healthcare industries in China;
our expectations regarding demand for and market acceptance of our products and services;
our expectations regarding our relationships with consumers, insurance carriers and other partners;
competition in the industries we operate;
our proposed use of proceeds; and
government policies and regulations relating to our industry.

You should read this annual report and the documents that we refer to in this annual report with the understanding that our actual future results may be materially different from and worse than what we expect. Other sections of this annual report include additional factors which could adversely impact our business and financial performance. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements.

2

PART I

Item 1.Identity of Directors, Senior Management and Advisers

Not applicable.

Item 2.Offer Statistics and Expected Timetable

Not applicable.

Item 3.Key Information

Waterdrop Inc. is not an operating company in China but rather a Cayman Islands holding company with no material operations of its own and no equity ownership in the VIEs (defined below). We conduct our operations primarily through (i) our subsidiaries in mainland China and (ii) the VIEs, with which we maintain contractual agreements. The laws and regulations of mainland China restrict and impose conditions on foreign direct investment in companies involved in the provision of value-added telecommunication services, insurance brokerage services or insurance agency services. Therefore, we operate such businesses in China through the variable interest entities, Zhuiqiu Jizhi, Shuidi Hubao, Shuidi Hulian, Zongqing Xiangqian and Guangmu Weichen, which we refer to as the VIEs in this annual report, and rely on contractual arrangements among our subsidiaries in mainland China, the VIEs and their shareholders to control the business operations of the VIEs. Revenues contributed by the VIEs accounted for 99.6%, 93.6% and 88.6% of our total net revenues for the fiscal years 2021, 2022 and 2023, respectively. As used in this annual report, “Waterdrop,” “we,” “us,” “our company” or “our” refers to Waterdrop Inc. and its subsidiaries. Investors in our ADSs thus are not purchasing equity interest in the VIEs but instead are purchasing equity interest in Waterdrop Inc., a Cayman Islands holding company, and may never directly hold equity interests in the VIEs in mainland China. The consolidated VIEs are mainland China companies conducting operations in mainland China, and their financial results have been consolidated into our consolidated financial statements under U.S. GAAP for accounting purposes. Waterdrop Inc. is a holding company with no operations of its own. We do not have any equity ownership in the consolidated VIEs.

Our corporate structure is subject to risks associated with our contractual arrangements with the VIEs. Investors may not directly hold equity interests in the VIEs or in the businesses that are conducted by the VIEs, and the VIE structure provides contractual exposure to foreign investment in mainland China-based companies which involve foreign investment restrictions. If the PRC government finds that the agreements that establish the structure for operating our business do not comply with the laws and regulations in mainland China, or if these regulations or their interpretations change in the future, we could be subject to severe penalties or be forced to relinquish our interests in those operations. This may result in the VIEs being deconsolidated, which would materially and adversely affect our operations, and our ADSs may decline significantly in value or become worthless. The legality and enforceability of the contractual agreements between our subsidiaries in mainland China, the VIEs, and their nominee shareholders, as a whole, have not been tested in a court of law in mainland China as of the date of this annual report. Our holding company, our subsidiaries in mainland China, the VIEs, and investors of our company face uncertainty about potential future actions by the PRC government that could affect the enforceability of the contractual arrangements with the VIEs and, consequently, significantly affect the financial performance of the VIEs and our company as a whole. The PRC regulatory authorities could disallow the VIE structure, which would likely result in a material adverse change in our operations, and our ordinary shares or our ADSs may decline significantly in value or become worthless. As such, the VIE structure involves unique risks to investors of our holding company. For a detailed description of the risks associated with our corporate structure, please refer to risks disclosed under “Item 3. Key Information—D. Risk Factors—Risks Related to Our Corporate Structure.”

3

We face various legal and operational risks and uncertainties related to doing business in China. Our business operations are primarily conducted in China, and we are subject to complex and evolving laws and regulations in mainland China. In recent years, the PRC government has issued statements and regulatory actions relating to areas such as regulatory approvals on offshore offerings, the use of VIE structure, anti-monopoly regulatory actions, and oversight on cybersecurity and data privacy. For example, on February 17, 2023, China Securities Regulatory Commission, or the CSRC, issued the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies and five supporting guidelines, which became effective on March 31, 2023. Pursuant to these regulations, China-based companies that directly or indirectly offer or list their securities in an overseas market must file with the CSRC within three business days after submitting their listing application documents to the regulator in the place of intended listing. These regulations also provide that a China-based company must file with the CSRC within three business days after completion of its follow-on offering of securities after it is listed in an overseas market. There remain uncertainties with respect to how the CSRC filing procedures under these regulations would be applied to, and implicate, the procedures, timetables and outcomes of our future offering or other capital raising activities. These risks could result in a material adverse change in our operations and the value of our ADSs, significantly limit or completely hinder our ability to continue to offer securities to investors and accept foreign investments or list on another foreign exchange, or cause the value of such securities to significantly decline or be worthless. For a detailed description of risks related to doing business in China, “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China.”

Risks and uncertainties arising from the legal system in mainland China, including risks and uncertainties regarding the enforcement of laws and quickly evolving rules and regulations in mainland China, could result in a material adverse change in our operations and the value of our ADSs. For more details, see “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—The legal system in mainland China is evolving, which leads to uncertainties that could adversely affect us.”

Our Holding Company Structure and VIE Contractual Arrangements

Waterdrop Inc. is a holding company with no material operations of its own. We conduct our operations primarily through our subsidiaries in mainland China and the VIEs. Our value-added telecommunication services, insurance brokerage services or insurance agency services in mainland China have been conducted through the VIEs in order to comply with the laws and regulations in mainland China, which restrict and impose conditions on foreign direct investment in companies involved in the provision of value-added telecommunication services, insurance brokerage services or insurance agency services.

4

The following diagram illustrates our corporate structure as of the date of this annual report, including our principal subsidiaries, the VIEs and the VIEs’ principal subsidiaries:

Graphic

Notes:

(1)

Mr. Peng Shen holds 100% of the equity interests in Beijing Shuidi Hubao Technology Co., Ltd.

(2)

Mr. Peng Shen and Mr. Guang Yang, each holds 99% and 1% of the equity interests in Beijing Zhuiqiu Jizhi Technology Co., Ltd.

(3)

Mr. Peng Shen and Mr. Wei Ran, each holds 99% and 1% of the equity interests in Beijing Zongqing Xiangqian Technology Co., Ltd.

(4)

Ms. Xiaolei Sun and Ms. Nian Liu, each holds 99% and 1% of the equity interests in Beijing Guangmu Weichen Technology Co., Ltd.

Permissions Required from the Authorities in Mainland China for Our Operations

We conduct our business primarily through our subsidiaries in mainland China, the VIEs and their subsidiaries in mainland China. Our operations in China are governed by the laws and regulations in mainland China. As of the date of this annual report, our subsidiaries in mainland China, the VIEs and their subsidiaries have obtained the requisite licenses and permits from the PRC governmental authorities that are material for the business operations of our holding company, the VIEs and their subsidiaries in mainland China, including, among others, licenses to conduct insurance brokerage business and insurance agency business, and license for provision of internet information services. Given the interpretation and implementation of the laws and regulations and the enforcement practice by governmental authorities are evolving, we may be required to obtain additional licenses, permits, filings or approvals for the functions and services of our platform in the future. For more detailed information, see “Item 3. Key Information—D. Risk Factors—Risks Related to Our Business—Any lack of requisite approvals, licenses or permits applicable to our business operation may have a material and adverse impact on our business and results of operations.”

5

As of the date of this annual report, except for the licenses and approvals that have been granted and except as disclosed in this annual report, we, our subsidiaries in mainland China and the VIEs are not required to obtain approval or permission from the CSRC, the Cyberspace Administration of China or any other entity that is required to approve the VIEs’ operations or required for us to offer securities to foreign investors under any currently effective laws, regulations and regulatory rules in mainland China. However, in connection with any future overseas capital markets activities, we may need to file with the CSRC, undergo a cybersecurity review conducted by the Cyberspace Administration of China, or meet other regulatory requirements that may be adopted in the future by the authorities in mainland China. To the extent such requirements are or become applicable, we cannot assure you that we would be able to comply with them. Any failure to obtain or delay in obtaining such approval or completing such procedures could subject us to restrictions and penalties imposed by the CSRC, the Cyberspace Administration of China or other PRC regulatory authorities, which could include fines and penalties on our operations in China, delays of or restrictions on the repatriation of the proceeds from our offshore offerings into mainland China, or other actions that could materially and adversely affect our business, financial condition, results of operations, and prospects, as well as the trading price of our ADSs. See “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—The PRC government’s significant oversight and discretion over our business operation could result in a material adverse change in our operations and the value of our ADSs.”

Furthermore, in connection with issuance of securities to foreign investors, in recent years, the PRC government has strengthened oversight over offerings that are conducted overseas and/or foreign investment in China-based issuers. Any such action could significantly limit or completely hinder our ability to conduct future offerings of securities to investors and accept foreign investments. For more detailed information, see “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—The filing, approval or other administration requirements of the CSRC or other PRC governmental authorities may be required in connection with our offshore offerings under the law in mainland China, and, if required, we cannot predict whether or for how long we will be able to complete such filing, obtain such approval or meet such requirements.”

The Holding Foreign Companies Accountable Act

Our auditor is located in mainland China. Pursuant to the Holding Foreign Companies Accountable Act, as amended by the Consolidated Appropriations Act that was signed into law on December 29, 2022, if the SEC determines that we have filed audit reports issued by a registered public accounting firm that has not been subject to inspections by the Public Company Accounting Oversight Board, or the PCAOB, for two consecutive years, the SEC will prohibit our shares or the ADSs from being traded on a national securities exchange or in the over-the-counter trading market in the United States. On December 16, 2021, the PCAOB issued a report to notify the SEC of its determination that the PCAOB was unable to inspect or investigate completely registered public accounting firms headquartered in mainland China and Hong Kong, including our auditor. In May 2022, the SEC conclusively listed us as a Commission-Identified Issuer under the HFCAA following the filing of our annual report on Form 20-F for the fiscal year ended December 31, 2021. On December 15, 2022, the PCAOB issued a report that vacated its December 16, 2021 determination and removed mainland China and Hong Kong from the list of jurisdictions where it is unable to inspect or investigate completely registered public accounting firms. As of the date of this annual report, the PCAOB has not issued any new determination that it is unable to inspect or investigate completely registered public accounting firms headquartered in any jurisdiction. For this reason, we do not expect to be identified as a Commission-Identified Issuer under the HFCAA after we file this annual report on Form 20-F. Each year, the PCAOB will determine whether it can inspect and investigate completely audit firms in mainland China and Hong Kong, among other jurisdictions. If the PCAOB determines in the future that it no longer has full access to inspect and investigate completely accounting firms in mainland China and Hong Kong and we continue to use an accounting firm headquartered in one of these jurisdictions to issue an audit report on our financial statements filed with the Securities and Exchange Commission, we would be identified as a Commission-Identified Issuer following the filing of the annual report on Form 20-F for the relevant fiscal year. There can be no assurance that we would not be identified as a Commission-Identified Issuer for any future fiscal year, and if we were so identified for two consecutive years, we would become subject to the prohibition on trading under the HFCAA. See “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—The PCAOB had historically been unable to inspect our auditor in relation to their audit work performed for our financial statements and the inability of the PCAOB to conduct inspections of our auditor in the past has deprived our investors with the benefits of such inspections” and “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—Our ADSs may be prohibited from trading in the United States under the HFCAA in the future if the PCAOB is unable to inspect or investigate completely auditors located in mainland China. The delisting of the ADSs, or the threat of their being delisted, may materially and adversely affect the value of your investment.”

6

Cash Transfers and Dividend Distribution

Waterdrop Inc., our Cayman Islands holding company, transfers cash to our wholly-owned Hong Kong subsidiary, by making capital contributions or providing loans, and our Hong Kong subsidiary transfers cash to our subsidiaries in mainland China by making capital contributions or providing loans to them.

Waterdrop Inc. and its subsidiaries are not able to make direct capital contribution to the VIEs and their subsidiaries. However, they may transfer cash to the VIEs by loans or by making payment to the VIEs for inter-group transactions.

The following table sets forth the amount of the transfers for the periods presented.

Years Ended December 31,

    

2021

    

2022

    

2023

(RMB in millions)

Capital contributions from Waterdrop Inc. to its subsidiaries

2,679

182

6

Loans from its subsidiaries to Waterdrop Inc.

382

 

777

 

1,650

Loans repayment received by its subsidiaries from Waterdrop Inc.

35

 

267

 

3,565

Loans from its subsidiaries to the VIEs and their subsidiaries

4,418

 

2,899

 

8,972

Loans repayment received by subsidiaries from VIEs and their subsidiaries

3,010

 

4,220

 

8,863

Service fees received by WFOE from the VIEs and their subsidiaries(1)

718

 

749

 

596

Note:

(1)

The cash flows between our WFOE and the VIEs and their subsidiaries included the service fees paid for services contemplated by the exclusive business cooperation agreements.

The VIEs may transfer cash to our WFOE by paying service fees according to the exclusive business cooperation agreements. Pursuant to these agreements between the VIEs and our WFOE, our WFOE has the exclusive right to provide the VIEs with consulting, technical services and other services required by the VIEs’ business. Without our WFOE’s prior written consent, the VIEs may not accept the same or similar consulting, technical services and other services provided by any third party during the term of the agreement. The VIEs agree to pay our WFOE service fees based on the operating profit generated by the VIEs on an annual basis. For the years ended December 31, 2021, 2022 and 2023, service fees of RMB718 million, RMB749 million and RMB596 million were paid to the WFOE by the VIEs under the agreements, respectively.

For the years ended December 31, 2021, 2022 and 2023, no dividends or distributions were made to Waterdrop Inc. by our subsidiaries. For the years ended December 31, 2021, 2022 and 2023, no dividends or distributions were made to U.S. investors.

For purposes of illustration, the following discussion reflects the hypothetical taxes that might be required to be paid within mainland China, assuming that: (i) we have taxable earnings, and (ii) we determine to pay a dividend in the future:

Taxation Scenario(1)

 

    

Statutory Tax and Standard Rates

 

Hypothetical pre-tax earnings(2)

 

100

%

Tax on earnings at statutory rate of 25%(3)

 

(25)

%

Net earnings available for distribution

 

75

%

Withholding tax at standard rate of 10%(4)

 

(7.5)

%

Net distribution to Waterdrop Inc./shareholders

 

67.5

%

Notes:

(1)

For purposes of this example, the tax calculation has been simplified. The hypothetical book pre-tax earnings amount, not considering timing differences, is assumed to equal taxable income in mainland China.

(2)

Under the terms of VIE agreements, our WFOE may charge the VIEs for services provided to the VIEs. These fees shall be recognized as expenses of the VIEs, with a corresponding amount as service income by our WFOE and eliminate in consolidation. For income tax purposes, our WFOE and the VIEs file income tax returns on a separate company basis. The fees paid are recognized as a tax deduction by the VIEs and as income by our WFOE and are tax neutral.

(3)

Certain of our subsidiaries qualifies for a 15% preferential income tax rate in mainland China. However, such rate is subject to qualification, is temporary in nature, and may not be available in a future period when distributions are paid. For purposes of this hypothetical example, the table above reflects a maximum tax scenario under which the full statutory rate would be effective.

7

(4)

The PRC Enterprise Income Tax Law imposes a withholding income tax of 10% on dividends distributed by a foreign-invested enterprise to its immediate holding company outside of mainland China. A lower withholding income tax rate of 5% is applied if the immediate holding company of the foreign-invested enterprise is registered in Hong Kong or other jurisdictions that have a tax treaty arrangement with mainland China, subject to a qualification review at the time of the distribution. For purposes of this hypothetical example, the table above assumes a maximum tax scenario under which the full withholding tax would be applied.

The table above has been prepared under the assumption that all profits of the VIEs will be distributed as fees to our WFOE under tax neutral contractual arrangements. If, in the future, the accumulated earnings of the VIE exceed the fees paid to our WFOE (or if the current and contemplated fee structure between the intercompany entities is determined to be non-substantive and disallowed by Chinese tax authorities), the VIEs could, as a matter of last resort, make a non-deductible transfer to our subsidiaries in mainland China for the amounts of the stranded cash in the VIEs. This would result in such transfer being non-deductible expenses for the VIEs but still taxable income for our WFOE.

As Waterdrop Inc. is a Cayman Islands holding company with no material operations of its own, its ability to pay dividends may depend upon dividends paid by our subsidiaries in mainland China. Our subsidiaries in mainland China in turn generate income from their own operations, and in addition enjoy all economic benefit and receive service fees from the VIEs pursuant to the exclusive business cooperation agreement with the VIEs. If our existing subsidiaries in mainland China or any newly formed ones incur debt on their own behalf in the future, the instruments governing their debt may restrict their ability to distribute earnings or pay dividends to us. Under the law in mainland China, each of our subsidiaries and the VIEs in mainland China is required to set aside at least 10% of its after-tax profits each year, if any, to fund certain statutory reserve funds until such reserve funds reach 50% of its registered capital. In addition, each of our subsidiaries and the VIEs in mainland China may allocate a portion of its after-tax profits based on mainland China accounting standards to a surplus fund at its discretion. The statutory reserve funds and the discretionary funds are not distributable as cash dividends. Remittance of dividends by a wholly foreign-owned company out of mainland China is subject to examination by the banks designated by the State Administration of Foreign Exchange, or SAFE, and declaration and payment of withholding tax. Additionally, if our subsidiaries in mainland China and the VIEs incur debt on their own behalf in the future, the instruments governing their debt may restrict their ability to pay dividends or make other distributions to us. Our subsidiaries in mainland China have not paid dividends and will not be able to pay dividends until it generates accumulated profits and meets the requirements for statutory reserve funds. For more details, see “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—Regulation in mainland China of loans to and direct investment in the entities in mainland China by offshore holding companies may delay us from using the proceeds of financing activities to make loans or additional capital contributions to our subsidiaries in mainland China and to make loans to the VIEs, which could materially and adversely affect our liquidity and our ability to fund and expand our business” and “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—Governmental regulation of currency conversion may limit our ability to utilize our revenues effectively and affect the value of your investment.”

8

Financial Information Related to the VIEs

The following table presents the condensed consolidating balance sheet data for the VIEs and other entities as of the dates presented.

As of December 31, 2023

Other non-

Waterdrop

Primary Beneficiary

VIE

VIEs and their

    

Inc.

    

of VIEs

    

subsidiaries

    

subsidiaries

    

Elimination

    

Consolidated

(RMB in thousands)

Cash and cash equivalents

 

134,265

 

24,195

 

119,126

 

119,319

 

 

396,905

Restricted cash

 

 

 

 

577,121

 

 

577,121

Short-term investments

 

557,753

 

1,108,531

 

771,944

 

558,299

 

 

2,996,527

Accounts receivable

 

 

113,605

 

8,563

 

570,942

 

 

693,110

Current contract assets

 

 

 

2,250

 

570,621

 

 

572,871

Amount due from related parties

 

 

 

 

65

 

 

65

Prepaid expense and other assets

 

14,929

 

17,122

 

6,369

 

151,426

 

 

189,846

Amounts due from the entities within our company

 

260,148

 

1,844,956

 

2,535,388

 

713,763

 

(5,354,255)

 

Non-current contract assets

 

 

 

1,065

 

133,318

 

 

134,383

Property, equipment and software, net

 

 

24,837

 

2,188

 

6,853

 

 

33,878

Intangible assets, net

 

 

15,807

 

 

174,113

 

(12,513)

 

177,407

Long-term investments

 

57,737

 

 

142,621

 

11,400

 

 

211,758

Investment in Non-VIE subsidiaries and amounts due from the entities within our company (non-current)

 

5,284,247

 

 

 

 

(5,284,247)

 

Investment in VIEs and their subsidiaries

 

 

(619,816)

 

 

 

619,816

 

Right of use assets, net

 

 

42,853

 

2,813

 

14,185

 

 

59,851

Deferred tax assets

 

 

 

 

24,190

 

 

24,190

Goodwill

 

 

 

 

80,751

 

 

80,751

Total assets

 

6,309,079

 

2,572,090

 

3,592,327

 

3,706,366

 

(10,031,199)

 

6,148,663

Amount due to related parties

 

 

9,509

 

 

 

 

9,509

Insurance premium payables

 

 

 

 

591,953

 

 

591,953

Deferred revenue

 

 

 

 

 

 

Accrued expenses and other current liabilities

 

197

 

86,871

 

19,918

 

490,698

 

 

597,684

Short-term loans

 

 

137,557

 

 

 

 

137,557

Current lease liabilities

 

 

21,523

 

1,271

 

10,114

 

 

32,908

Amounts due to the entities within our company

 

1,723,188

 

1,535,096

 

1,159,772

 

3,064,151

 

(7,482,207)

 

Non-current lease liabilities

 

 

22,144

 

1,523

 

3,626

 

 

27,293

Deferred tax liabilities

72,880

425

73,305

Total liabilities

1,723,385

1,812,700

1,182,484

4,233,422

(7,481,782)

1,470,209

9

As of December 31, 2022

Other non-

Waterdrop

Primary Beneficiary

VIE

VIEs and their

    

Inc.

    

of VIEs

    

subsidiaries

    

subsidiaries

    

Elimination

    

Consolidated

(RMB in thousands)

Cash and cash equivalents

351,817

    

579,504

    

251,675

    

391,175

    

    

1,574,171

Restricted cash

 

 

 

517,364

 

 

517,364

Short-term investments

310,799

 

1,472,034

 

347,544

 

 

 

2,130,377

Accounts receivable

 

89,398

 

25

 

586,373

 

 

675,796

Current contract assets

 

 

 

450,085

 

 

450,085

Amount due from related parties

 

 

 

358

 

 

358

Prepaid expense and other assets

81,162

 

18,549

 

10,703

 

232,054

 

 

342,468

Amounts due from the entities within our company

118,426

 

1,446,143

 

4,624,598

 

433,075

 

(6,622,242)

 

Non-current contract assets

 

 

 

103,591

 

 

103,591

Property, equipment and software, net

 

24,061

 

6

 

7,330

 

 

31,397

Intangible assets, net

 

18,171

 

 

53,192

 

(14,749)

 

56,614

Long-term investments

2,069

 

 

 

9,900

 

 

11,969

Investment in Non-VIE subsidiaries

4,914,981

 

 

 

 

(4,914,981)

 

Investment in VIEs and their subsidiaries

 

(730,423)

 

 

 

730,423

 

Right of use assets, net

 

2,762

 

195

 

15,490

 

 

18,447

Deferred tax assets

 

 

 

6,166

 

 

6,166

Goodwill

 

 

 

3,420

 

 

3,420

Total assets

5,779,254

 

2,920,199

 

5,234,746

 

2,809,573

 

(10,821,549)

 

5,922,223

Amount due to related parties

 

11,509

 

 

44

 

 

11,553

Insurance premium payables

 

 

 

516,661

 

 

516,661

Accrued expenses and other current liabilities

7,380

 

120,296

 

2,451

 

453,996

 

 

584,123

Current lease liabilities

 

37

 

195

 

9,122

 

 

9,354

Amounts due to the entities within our company

1,005,746

 

2,650,573

 

81,011

 

2,526,194

 

(6,263,524)

 

Non-current lease liabilities

 

 

 

4,701

 

 

4,701

Deferred tax liabilities

 

 

 

29,278

 

425

 

29,703

Total liabilities

 

1,013,126

 

2,782,415

 

83,657

 

3,539,996

 

(6,263,099)

 

1,156,095

10

The following table presents the condensed consolidating statements of operations for the VIEs and other entities for the periods presented.

For the year ended December 31, 2023

Other non-

Waterdrop

Primary

VIE

VIEs and their

    

Inc.

    

Beneficiary of VIEs

    

subsidiaries

    

subsidiaries

    

Elimination

    

Consolidated

(RMB in thousands)

Operating revenue, net

 

 

824,244

 

51,235

 

2,331,678

 

(576,450)

 

2,630,707

Operating costs

 

 

(137,866)

 

(44,634)

 

(1,171,282)

 

158,238

 

(1,195,544)

Sales and marketing expenses

 

(12,317)

 

(155,478)

 

(18,587)

 

(554,069)

 

 

(740,451)

General and administrative expenses

 

(73,712)

 

(257,382)

 

(7,612)

 

(484,180)

 

420,491

 

(402,395)

Research and development expenses

 

(1,031)

 

(267,000)

 

9

 

(31,038)

 

 

(299,060)

Total operating costs and expenses

 

(87,060)

 

(817,726)

 

(70,824)

 

(2,240,569)

 

578,729

 

(2,637,450)

Operating (loss)/profit

 

(87,060)

 

6,518

 

(19,589)

 

91,109

 

2,279

 

(6,743)

Equity in profit of subsidiaries and VIEs

 

221,959

 

227,813

 

 

 

(449,772)

 

Net profit/(loss)

 

167,221

 

296,391

 

(77,968)

 

121,441

 

(343,400)

 

163,685

For the year ended December 31, 2022

Other non-

Waterdrop

Primary

VIE

VIEs and their

    

Inc.

    

Beneficiary of VIEs

    

subsidiaries

    

subsidiaries

    

Elimination

    

Consolidated

(RMB in thousands)

Operating revenue, net

 

775,573

 

1,795

 

2,623,738

 

(599,338)

 

2,801,768

Operating costs

 

(120,168)

 

(882)

 

(1,118,686)

 

220,374

 

(1,019,362)

Sales and marketing expenses

(16,509)

 

(118,106)

 

(7,002)

 

(482,861)

 

 

(624,478)

General and administrative expenses

(121,636)

 

(210,666)

 

(2,070)

 

(435,204)

 

380,925

 

(388,651)

Research and development expenses

(15,458)

 

(256,774)

 

(27)

 

(19,031)

 

 

(291,290)

Total operating costs and expenses

(153,603)

 

(705,714)

 

(9,981)

 

(2,055,782)

 

601,299

 

(2,323,781)

Operating (loss)/profit

(153,603)

 

69,859

 

(8,186)

 

567,956

 

1,961

 

477,987

Equity in profit of subsidiaries and VIEs

730,943

 

718,807

 

 

 

(1,449,750)

 

Net profit/(loss)

607,717

 

822,606

 

(91,663)

 

611,235

 

(1,342,178)

 

607,717

For the year ended December 31, 2021

Other non-

Waterdrop

Primary

VIE

VIEs and their

    

Inc.

    

Beneficiary of VIEs

    

subsidiaries

    

subsidiaries

    

Elimination

    

Consolidated

(RMB in thousands)

Operating revenue, net

2,279

 

757,692

 

106

 

3,193,807

 

(747,970)

 

3,205,914

Operating costs

 

(171,728)

 

 

(882,747)

 

 

(1,054,475)

Sales and marketing expenses

(10,902)

 

(160,242)

 

(1,356)

 

(2,932,269)

 

 

(3,104,769)

General and administrative expenses

(214,856)

 

(207,407)

 

(1,198)

 

(853,908)

 

746,847

 

(530,522)

Research and development expenses

(25,056)

 

(329,291)

 

 

(24,643)

 

 

(378,990)

Total operating costs and expenses

(250,814)

 

(868,668)

 

(2,554)

 

(4,693,567)

 

746,847

 

(5,068,756)

Operating loss

(248,535)

 

(110,976)

 

(2,448)

 

(1,499,760)

 

(1,123)

 

(1,862,842)

Equity in loss of subsidiaries and VIEs

(1,332,101)

 

(1,250,773)

 

 

 

2,582,874

 

Net (loss)/profit

(1,574,080)

 

(1,355,152)

 

23,051

 

(1,253,808)

 

2,585,909

 

(1,574,080)

11

The following table presents condensed consolidating cash flow data for the VIEs and other entities for the years ended presented.

For the year ended December 31, 2023

    

Waterdrop

    

Primary Beneficiary

    

Other non-VIE

    

VIEs and their

    

    

Inc.

of VIEs

subsidiaries

subsidiaries

Elimination

Consolidated

(RMB in thousands)

Net cash provided by/(used in) operating activities

621,178

 

69,715

 

(536,388)

 

252,011

 

 

406,516

Net cash (used in)/provided by investing activities

(299,737)

 

(1,104,857)

 

351,187

 

(573,368)

 

453,815

 

(1,172,960)

Net cash (used in)/provided by financing activities

(514,315)

 

476,331

 

5,933

 

108,628

 

(453,815)

 

(377,238)

For the year ended December 31, 2022

    

Waterdrop

    

Primary Beneficiary

    

Other non-VIE

    

VIEs and their

    

    

Inc.

of VIEs

subsidiaries

subsidiaries

Elimination

Consolidated

(RMB in thousands)

Net cash provided by/(used in) operating activities

534,951

    

(50,520)

    

(202,462)

    

483,736

    

    

765,705

Net cash (used in)/provided by investing activities

(112,500)

 

252,633

 

139,584

 

347,545

 

(767,081)

 

(139,819)

Net cash (used in)/provided by financing activities

(57,293)

 

372,836

 

181,567

 

(1,321,648)

 

767,081

 

(57,457)

For the year ended December 31, 2021

    

Waterdrop

    

Primary Beneficiary

    

Other non-VIE

    

VIEs and their

    

    

Inc.

of VIEs

subsidiaries

subsidiaries

Elimination

Consolidated

(RMB in thousands)

Net cash provided by/(used in) operating activities

320,097

 

154,955

 

(652,024)

 

(919,680)

 

 

(1,096,652)

Net cash (used in)/provided by investing activities

(2,458,126)

 

(148,189)

 

(2,228,597)

 

(99,240)

 

4,087,254

 

(846,898)

Net cash provided by/(used in) financing activities

2,128,529

 

(8,859)

 

2,678,979

 

1,408,275

 

(4,087,254)

 

2,119,670

12

A.[Reserved]

The following selected consolidated statements of comprehensive (loss)/income data for the years ended December 31, 2021, 2022 and 2023, selected consolidated balance sheet data as of December 31, 2022 and 2023 and selected consolidated cash flow data for the years ended December 31, 2021, 2022 and 2023 have been derived from our audited consolidated financial statements included elsewhere in this annual report. The following selected consolidated statements of comprehensive loss data for the years ended December 31, 2019 and 2020, selected consolidated balance sheet data as of December 31, 2019, 2020 and 2021 and selected consolidated cash flow data for the years ended December 31, 2019 and 2020 have been derived from our audited consolidated financial statements not included in this annual report. Our consolidated financial statements are prepared and presented in accordance with U.S. GAAP. You should read this “Selected Financial Data” section together with our consolidated financial statements and the related notes and “Item 5. Operating and Financial Review and Prospects” included elsewhere in this annual report. Our historical results are not necessarily indicative of results we expect for future periods.

The following table sets forth a summary of our consolidated statements of comprehensive (loss)/income for the years ended December 31, 2019, 2020, 2021, 2022 and 2023.

For the Year Ended December 31,

2019

2020

2021

2022

2023

    

RMB

    

RMB

    

RMB

    

RMB

    

RMB

    

US$

(in thousands, except for share and per share data)

Operating revenue, net

 

1,510,965

 

3,027,948

 

3,205,914

 

2,801,768

 

2,630,707

 

370,527

Operating costs and expenses

 

 

 

 

 

 

Operating costs

 

(291,310)

 

(742,258)

 

(1,054,475)

 

(1,019,362)

 

(1,195,544)

 

(168,389)

Sales and marketing expenses

 

(1,056,494)

 

(2,130,535)

 

(3,104,769)

 

(624,478)

 

(740,451)

 

(104,290)

General and administrative expenses

 

(142,995)

 

(407,171)

 

(530,522)

 

(388,651)

 

(402,395)

 

(56,676)

Research and development expenses

 

(214,646)

 

(244,230)

 

(378,990)

 

(291,290)

 

(299,060)

 

(42,122)

Total operating costs and expenses

 

(1,705,445)

 

(3,524,194)

 

(5,068,756)

 

(2,323,781)

 

(2,637,450)

 

(371,477)

Operating (loss)/profit

 

(194,480)

 

(496,246)

 

(1,862,842)

 

477,987

 

(6,743)

 

(950)

Other income/(expenses)

Interest income

 

10,533

 

26,515

 

48,662

 

81,713

 

136,043

 

19,161

Fair value change of warrant

 

 

(150,685)

 

 

 

 

Foreign currency exchange gain/(loss)

 

4,152

 

(1,335)

 

9,349

 

4,064

 

4,342

 

612

Others, net

 

817

 

8,052

 

9,764

 

66,929

 

30,598

 

4,310

(Loss)/profit before income tax, and share of results of equity method investee

 

(178,978)

 

(613,699)

 

(1,795,067)

 

630,693

 

164,240

 

23,133

Income tax (expense)/benefit

 

(142,528)

 

(50,155)

 

220,987

 

(22,976)

 

(555)

 

(78)

Share of results of equity method investee

 

(29)

 

(15)

 

 

 

 

Net (loss)/profit

 

(321,535)

 

(663,869)

 

(1,574,080)

 

607,717

 

163,685

 

23,055

Deemed dividend on modification on preferred shares

 

 

(67,975)

 

 

 

 

Deemed dividend upon issuance of warrants

 

 

(90,268)

 

 

 

 

Preferred shares redemption value accretion

 

(136,839)

 

(285,668)

 

(152,287)

 

 

 

Net loss attributable to mezzanine equity classified as non-controlling interest

(3,536)

(498)

Net (loss)/profit attributable to ordinary shareholders

 

(458,374)

 

(1,107,780)

 

(1,726,367)

 

607,717

 

167,221

 

23,553

Weighted average number of ordinary shares used in computing net (loss)/profit per share

 

 

 

 

 

 

Basic

 

1,203,526,000

 

1,174,583,516

 

2,990,507,749

 

3,921,388,720

 

3,769,679,736

 

3,769,679,736

Diluted

 

1,203,526,000

 

1,174,583,516

 

2,990,507,749

 

4,022,467,160

 

3,880,861,496

 

3,880,861,496

Net (loss)/profit per share attributable to ordinary shareholders

 

 

 

 

 

 

Basic

 

(0.38)

 

(0.94)

 

(0.58)

 

0.15

 

0.04

 

0.01

Diluted

 

(0.38)

 

(0.94)

 

(0.58)

 

0.15

 

0.04

 

0.01

13

The following table presents our selected consolidated balance sheet data as of December 31, 2019, 2020, 2021, 2022 and 2023.

As of December 31,

 

2019

2020

2021

2022

2023

 

    

RMB

RMB

    

RMB

    

RMB

    

RMB

    

US$

 

(in thousands)

 

Selected Consolidated Balance Sheet Data:

 

  

 

  

 

  

 

  

 

  

Cash and cash equivalents

 

964,476

1,061,962

817,719

1,574,171

396,905

55,903

Restricted cash

 

329,676

261,387

667,664

517,364

577,121

81,286

Short-term investments

 

60,278

1,193,160

1,969,362

2,130,377

2,996,527

422,052

Accounts receivable, net

 

252,499

539,791

643,843

675,796

693,110

97,623

Contract assets

 

617,688

848,550

593,500

553,676

707,254

99,614

Total assets

 

2,555,906

4,705,055

5,250,599

5,922,223

6,148,663

866,020

Insurance premium payables(1)

 

320,327

607,326

685,028

516,661

591,953

83,375

Deferred revenue(2)

 

21,670

22,017

803

Accrued expenses and other current liabilities(3)

 

496,530

595,606

 

498,752

 

584,123

 

597,684

 

84,182

Short-term loans

137,557

19,374

Deferred tax liabilities(4)

 

167,601

225,745

 

13,551

 

29,703

 

73,305

 

10,325

Total liabilities

 

1,054,394

1,524,743

 

1,277,173

 

1,156,095

 

1,470,209

 

207,074

Total mezzanine equity

 

2,207,831

4,837,336

 

 

 

92,760

 

13,065

Total shareholders’ (deficit)/equity

 

(706,319)

(1,657,024)

 

3,973,426

 

4,766,128

 

4,585,694

 

645,881

(1)

Includes amounts of the consolidated VIEs and subsidiaries of VIEs without recourse to us of RMB320.2 million, RMB607.3 million, RMB685.0 million, RMB516.7 million and RMB592.0 million as of December 31, 2019, 2020, 2021, 2022 and 2023, respectively.

(2)

Includes amounts of the consolidated VIEs and subsidiaries of VIEs without recourse to us of RMB21.7 million, RMB22.0 million, RMB0.8 million, nil and nil as of December 31, 2019, 2020, 2021, 2022 and 2023, respectively.

(3)

Includes amounts of the consolidated VIEs and subsidiaries of VIEs without recourse to us of RMB428.8 million, RMB447.2 million, RMB413.4 million, RMB454.0 million and RMB490.7 million as of December 31, 2019, 2020, 2021, 2022 and 2023, respectively.

(4)

Includes amounts of the consolidated VIEs and subsidiaries of VIEs without recourse to us of RMB167.2 million, RMB225.3 million, RMB13.1 million, RMB29.3 million and RMB72.9 million as of December 31, 2019, 2020, 2021, 2022 and 2023, respectively.

The following table sets forth our selected consolidated cash flow data for the years ended December 31, 2019, 2020, 2021, 2022 and 2023.